Literature DB >> 18480115

Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

Bernard Vrijens1, Gäbor Vincze, Paulus Kristanto, John Urquhart, Michel Burnier.   

Abstract

OBJECTIVE: To describe characteristics of dosing history in patients prescribed a once a day antihypertensive medication.
DESIGN: Longitudinal database study.
SETTING: Clinical studies archived in database for 1989-2006. PARTICIPANTS: Patients who participated in the studies whose dosing histories were available through electronic monitoring. MAIN OUTCOME MEASURES: Persistence with prescribed antihypertensive treatment and execution of their once a day drug dosing regimens.
RESULTS: The database contained dosing histories of 4783 patients with hypertension. The data came from 21 phase IV clinical studies, with lengths ranging from 30 to 330 days and involving 43 different antihypertensive drugs, including angiotensin II receptor blockers (n=2088), calcium channel blockers (n=937), angiotensin converting enzyme inhibitors (n=665), beta blockers (n=195), and diuretics (n=155). About half of the patients who were prescribed an antihypertensive drug had stopped taking it within one year. On any day, patients who were still engaged with the drug dosing regimen omitted about 10% of the scheduled doses: 42% of these omissions were of a single day's dose, whereas 43% were part of a sequence of several days (three or more days-that is, drug "holidays"). Almost half of the patients had at least one drug holiday a year. The likelihood that a patient would discontinue treatment early was inversely related to the quality of his or her daily execution of the dosing regimen.
CONCLUSIONS: Early discontinuation of treatment and suboptimal daily execution of the prescribed regimens are the most common facets of poor adherence with once a day antihypertensive drug treatments. The shortfalls in drug exposure that these dosing errors create might be a common cause of low rates of blood pressure control and high variability in responses to prescribed antihypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480115      PMCID: PMC2386633          DOI: 10.1136/bmj.39553.670231.25

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  30 in total

1.  Characteristics of patients with uncontrolled hypertension in the United States.

Authors:  D J Hyman; V N Pavlik
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

2.  Pharmacodynamics of variable patient compliance: implications for pharmaceutical value.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-09-07       Impact factor: 15.470

Review 3.  Compliance in clinical trials.

Authors:  T Pullar; S Kumar; M Feely
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

4.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

5.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

Authors:  J J Caro; J L Speckman; M Salas; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

6.  Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.

Authors:  Bernard Vrijens; Eric Tousset; Richard Rode; Richard Bertz; Steve Mayer; John Urquhart
Journal:  J Clin Pharmacol       Date:  2005-04       Impact factor: 3.126

7.  Prediction of diltiazem plasma concentration curves from limited measurements using compliance data.

Authors:  A Rubio; C Cox; M Weintraub
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

8.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

9.  Improved compliance measures: applications in an ambulatory hypertensive drug trial.

Authors:  P Rudd; S Ahmed; V Zachary; C Barton; D Bonduelle
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875

10.  Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact.

Authors:  J Urquhart
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

View more
  239 in total

1.  Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Authors:  Edeltraut Kröger; Rob van Marum; Patrick Souverein; Toine Egberts
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

2.  Taking immunosuppressive medications effectively (TIMELink): a pilot randomized controlled trial in adult kidney transplant recipients.

Authors:  Cynthia Russell; Vicki Conn; Catherine Ashbaugh; Richard Madsen; Mark Wakefield; Andrew Webb; Deanna Coffey; Leanne Peace
Journal:  Clin Transplant       Date:  2010-11-16       Impact factor: 2.863

3.  [Diuretics in the treatment of hypertension. Efficacy, safety and tolerability].

Authors:  R Düsing
Journal:  Internist (Berl)       Date:  2011-12       Impact factor: 0.743

4.  Predictors of objectively measured medication nonadherence in adults with heart failure.

Authors:  Barbara Riegel; Christopher S Lee; Sarah J Ratcliffe; Sabina De Geest; Sheryl Potashnik; Megan Patey; Steven L Sayers; Lee R Goldberg; William S Weintraub
Journal:  Circ Heart Fail       Date:  2012-05-30       Impact factor: 8.790

5.  Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care.

Authors:  Jamie J Coleman; Sarah E McDowell; Stephen J W Evans; Paramjit S Gill; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

6.  Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan.

Authors:  Yuichi Tasaka; Daiki Yasunaga; Mamoru Tanaka; Akihiro Tanaka; Takashige Asakawa; Ikuo Horio; Yoshiro Miyauchi; Hiroaki Araki
Journal:  Int J Clin Pharm       Date:  2016-01-08

7.  Drug persistence and adherence in the treatment of overactive bladder.

Authors:  Sidney B Radomski
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

8.  Pharmacist-based antihypertensive medication review and assignment of morning versus evening dosing of once-daily antihypertensive medications: A pilot study to assess feasibility and efficacy in chronic kidney disease patients.

Authors:  Julia R Smith; Lisa Hillman; Paul E Drawz
Journal:  Clin Exp Hypertens       Date:  2017-12-06       Impact factor: 1.749

9.  Association Between Health Literacy and Medication Adherence Among Hispanics with Hypertension.

Authors:  Maichou Lor; Theresa A Koleck; Suzanne Bakken; Sunmoo Yoon; Ann-Margaret Dunn Navarra
Journal:  J Racial Ethn Health Disparities       Date:  2019-01-03

10.  Lazy sunday afternoons: the negative impact of interruptions in patients' daily routine on adherence to oral antidiabetic medication. A multilevel analysis of electronic monitoring data.

Authors:  M Vervloet; P Spreeuwenberg; M L Bouvy; E R Heerdink; D H de Bakker; L van Dijk
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.